Results 41 to 50 of about 125,001 (364)

Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]

, 2018
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA, Robert H., Saad, MD, Hassan, Smith, MD, Michelle, Tjoumakaris, MD, Stavropoula, Zarzour, MD, Hekmat   +9 more
core   +2 more sources

Atorvastatin and Clopidogrel [PDF]

Circulation, 2003
To the Editor: I would like to comment on the recent editorial by Serebruany et al1 in which the study results by Lau et al2 are discussed. It is argued that these results, which are suggestive of a clinically relevant interaction between clopidogrel and atorvastatin, are in conflict with those published previously by Serebruany et al.3 According to ...
openaire   +3 more sources

Acute myocardial infarction with normal electrocardiogram and biomarkers of cardiac injury: A case report

Annals of Noninvasive Electrocardiology, Volume 28, Issue 1, January 2023., 2023
AMI with normal ECG and biomarkers of cardiac injury is exceedingly rare. The clinical manifestations of AMI were complex and varied, especially that the patients with atypical AMI were increasing in clinical practice. Caution should be exercised to exclude AMI in patients with chest pain and both normal ECG and biomarkers of cardiac injury.
Ke‐Lan Zha, Wen Chen, Qiang Ye
wiley   +1 more source

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2019
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option.
Hirotoshi Watanabe, T. Domei, T. Morimoto, M. Natsuaki, H. Shiomi, T. Toyota, M. Ohya, S. Suwa, K. Takagi, M. Nanasato, Yoshiki Hata, Masahiro Yagi, N. Suematsu, Takafumi Yokomatsu, I. Takamisawa, M. Doi, T. Noda, H. Okayama, Yoshitane Seino, T. Tada, H. Sakamoto, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, K. Hanaoka, Y. Morino, K. Kozuma, K. Kadota, Y. Furukawa, Y. Nakagawa, Takeshi Kimura   +34 more
semanticscholar   +1 more source

Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset [PDF]

, 2010
<p><b>Background and Purpose:</b> Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke.</p> <p><b>Methods:</b> We ...
Ahmed, N., Diedler, J., Ford, G.A., Lees, K.R., Luijckx, G.J., Overgaard, K., Ringleb, P., Soinne, L., Sykora, M., Uyttenboogaart, M., Wahlgren, N.   +10 more
core   +2 more sources

Clopidogrel and Aspirin in Acute Ischemic Stroke and High‐Risk TIA

New England Journal of Medicine, 2018
BACKGROUND Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA).
S. Johnston, D. Easton, M. Farrant, W. Barsan, R. Conwit, C. Johnston, J. Easton, J. Elm, A. Kim, Anne S. Lindbald, Y. Palesch   +10 more
semanticscholar   +1 more source

Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Journal of the American Medical Association (JAMA), 2020
Importance Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial.
S. You, Yeunsook Rho, B. Bikdeli, Jiwoo Kim, Anastasios Siapos, J. Weaver, A. Londhe, Jaehyeong Cho, Jimyung Park, M. Schuemie, M. Suchard, D. Madigan, G. Hripcsak, Aakriti Gupta, C. Reich, P. Ryan, R. W. Park, H. Krumholz   +17 more
semanticscholar   +1 more source

Clopidogrel resistance: The way forward

Indian Heart Journal, 2014
Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj   +1 more source

Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. [PDF]

PLoS ONE, 2013
BACKGROUND: The efficacy of clopidogrel is inconclusive in the chronic kidney disease (CKD) population with acute coronary syndrome (ACS). Furthermore, CKD patients are prone to bleeding with antiplatelet therapy.
Tsung-Hsien Lin, Wen-Ter Lai, Ho-Tsung Hsin, Ai-Hsien Li, Chun-Li Wang, Chi-Tai Kuo, Juey-Jen Hwang, Fu-Tien Chiang, Shu-Chen Chang, ACS Full Spectrum Registry Investigators   +9 more
doaj   +1 more source

Cytochrome p-450 polymorphisms and response to clopidogrel.

New England Journal of Medicine, 2009
BACKGROUND Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.
J. Mega, S. Close, S. Wiviott, Lei-Bin Shen, R. Hockett, J. Brandt, J. Walker, E. Antman, W. Macias, E. Braunwald, M. Sabatine   +10 more
semanticscholar   +1 more source